Ultragenyx Pharmaceutical Inc. (RARE)’s Double Bottom Pattern Points to Higher Stock Risks

February 20, 2018 - By Peter Erickson

Investors sentiment decreased to 1.19 in 2017 Q3. Its down 0.65, from 1.84 in 2017Q2. It fall, as 17 investors sold Ultragenyx Pharmaceutical Inc. shares while 40 reduced holdings. 15 funds opened positions while 53 raised stakes. 39.75 million shares or 1.85% less from 40.50 million shares in 2017Q2 were reported.
Rmb Cap Management Ltd Liability Corporation reported 47,895 shares stake. Kazazian Asset Mgmt Ltd Llc accumulated 0.57% or 8,747 shares. 2,929 were accumulated by Sg Americas Ltd Llc. Citigroup holds 0% or 24,416 shares in its portfolio. Hood River Cap Mgmt Llc owns 114,294 shares for 0.39% of their portfolio. Smith Asset Mngmt Grp Inc Ltd Partnership invested 0.02% in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE). Cwm Limited Company accumulated 3 shares. First Trust Advisors Ltd Partnership holds 0.07% of its portfolio in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) for 525,878 shares. Jpmorgan Chase & reported 191,204 shares. Tower Research Capital (Trc) holds 0.01% or 2,611 shares. Dekabank Deutsche Girozentrale invested 0.01% of its portfolio in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE). Guggenheim Cap Ltd holds 0.01% or 68,994 shares. Amer Century stated it has 29,971 shares. Moreover, Iguana Healthcare Management Ltd Liability has 1.49% invested in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) for 50,000 shares. 472,019 are held by Northern Tru Corporation.

The chart of Ultragenyx Pharmaceutical Inc. (RARE) shows a double bottom with $42.88 target or 9.00 % below today’s $47.12 share price. The 9 months chart pattern indicates high risk for the $2.21 billion company. It was reported on Feb, 20 by Finviz.com. If the $42.88 price target is reached, the company will be worth $198.81 million less. Double bottoms are rare but powerful chart patterns.

The stock decreased 0.84% or $0.4 during the last trading session, reaching $47.12. About 344,776 shares traded. Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) has declined 6.49% since February 20, 2017 and is downtrending. It has underperformed by 23.19% the S&P500.

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Ratings Coverage

Among 21 analysts covering Ultragenyx Pharmaceutical Inc (NASDAQ:RARE), 14 have Buy rating, 1 Sell and 6 Hold. Therefore 67% are positive. Ultragenyx Pharmaceutical Inc had 58 analyst reports since July 27, 2015 according to SRatingsIntel. The rating was maintained by Robert W. Baird with “Buy” on Tuesday, August 22. Morgan Stanley downgraded it to “Equal Weight” rating and $126 target in Monday, July 27 report. Leerink Swann initiated Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) on Friday, February 19 with “Outperform” rating. The firm earned “Buy” rating on Tuesday, December 22 by Canaccord Genuity. The firm has “Buy” rating given on Thursday, November 16 by Canaccord Genuity. Stifel Nicolaus maintained Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) rating on Tuesday, August 22. Stifel Nicolaus has “Buy” rating and $85.0 target. The stock of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) earned “Outperform” rating by Raymond James on Tuesday, September 1. The stock has “Outperform” rating by Robert W. Baird on Friday, November 3. The firm has “Buy” rating given on Friday, June 23 by Stifel Nicolaus. The firm earned “Outperform” rating on Thursday, September 14 by Wedbush.

More important recent Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) news were published by: Globenewswire.com which released: “Ultragenyx Announces Pricing of Public Offering of Common Stock” on January 24, 2018, also Globenewswire.com published article titled: “Ultragenyx Appoints Camille L. Bedrosian, MD as Chief Medical Officer and …”, Seekingalpha.com published: “Ultragenyx Pharmaceutical: Buy The Offering” on January 24, 2018. More interesting news about Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) was released by: Globenewswire.com and their article: “Ultragenyx to Host Conference Call for Fourth Quarter and Full Year 2017 …” with publication date: February 14, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.